Circulating tumor DNA (ctDNA), which is fragmented DNA released by tumor cells into the bloodstream, provides crucial information about cancer presence and progression. Liquid biopsies that enable the extraction and analysis of ctDNA from blood samples are promising tools for cancer diagnosis and monitoring. However, detecting ctDNA can be challenging, especially in early stage cancers where its levels are low. In this webinar, Shervin Tabrizi will discuss how he developed priming agents that enhance the sensitivity of ctDNA detection, paving the way for earlier identification of small tumors and minimal residual diseases.
Topics to be covered
- Developing nanoparticle- and antibody-based priming agents to enhance ctDNA recovery from blood
- Testing priming agents for early tumor detection in nonclinical models
Thursday, September 19th, 2024 | 1:00 PM - 2:00 PM Eastern Time
This webinar will be available to view live and on demand.
Speaker
Shervin Tabrizi, MD
Postdoctoral Scholar, Broad Institute
Physician-scientist, Massachusetts General Hospital